

2018 Current Fiscal Year Report: Uniform Formulary Beneficiary Advisory Panel

Report Run Date: 06/16/2019 10:33:49 AM

1. Department or Agency		2. Fiscal Year	
Department of Defense		2018	
3. Committee or Subcommittee		3b. GSA Committee No.	
Uniform Formulary Beneficiary Advisory Panel		9484	
4. Is this New During Fiscal Year?	5. Current Charter	6. Expected Renewal Date	7. Expected Term Date
No	08/01/2018	08/01/2020	
8a. Was Terminated During FiscalYear?	8b. Specific Termination Authority	8c. Actual Term Date	
No			
9. Agency Recommendation for Next FiscalYear	10a. Legislation Req to Terminate?	10b. Legislation Pending?	
Continue	No	Not Applicable	
11. Establishment Authority Statutory (Congress Created)			
12. Specific Establishment Authority	13. Effective Date	14. Committee Type	14c. Presidential?
10 U.S.C. § 1074g(c)	10/05/1999	Continuing	No
15. Description of Committee Scientific Technical Program Advisory Board			
16a. Total Number of Reports	No Reports for this FiscalYear		
17a. Open Meetings	17b. Closed Meetings	17c. Partially Closed Meetings	17d. Total Meetings
4	0	0	4

Meetings and Dates

Purpose	Start	End
The Panel will review and comment on the recommendations made to the Deputy Director, Defense Health Agency (DHA) by the Pharmacy and Therapeutics Committee regarding the Uniform Formulary.	01/04/2018	01/04/2018
The Panel will review and comment on the recommendations made to the Director, Defense Health Agency (DHA) by the Pharmacy and Therapeutics Committee regarding the Uniform Formulary	04/05/2018	04/05/2018
The Panel will review and comment on the recommendations made to the Director, Defense Health Agency (DHA) by the Pharmacy and Therapeutics Committee regarding the Uniform Formulary	07/12/2018	07/12/2018
The Panel will review and comment on the recommendations made to the Director, Defense Health Agency (DHA) by the Pharmacy and Therapeutics Committee regarding the Uniform Formulary	09/27/2018	09/27/2018

Number of Committee Meetings Listed: 4

	Current FY	Next FY
18a(1). Personnel Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$35,000.00	\$35,000.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$2,000.00	\$3,000.00

18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$7,700.00	\$7,700.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$7,800.00	\$8,500.00
18d. Total	\$52,500.00	\$54,200.00
19. Federal Staff Support Years (FTE)	0.35	0.35

20a. How does the Committee accomplish its purpose?

The Panel will meet an estimate of four times a year to review and comment on the development of the Uniform Formulary by the DoD Pharmacy and Therapeutics Committee. The Director, Defense Health Agency is required to consider the comments of the panel before making his final decision.

20b. How does the Committee balance its membership?

The Panel's membership includes family members of active duty and retired military personnel, members of retiree organizations, TRICARE healthcare contractors, and medical professionals from outside of DoD.

20c. How frequent and relevant are the Committee Meetings?

Per the Charter, the estimated number of Panel meeting is 4 per year. DoD implemented its Congressionally-mandated 3-tier Uniform Formulary (UF) in 2005 which required development of a transparent formulary management process that accesses medications for formulary status based on an evidence-based clinical and cost-effectiveness evaluation; open/equitable price competition; and to establish the Beneficiary Advisory Panel (BAP) which provides an opportunity for beneficiaries to comment on the DoD Pharmacy and Therapeutics (P&T) Committee's formulary recommendations before approval by the DHA Director. The BAP concept is unique to DoD. It provides transparency and credibility from a beneficiary perspective to the UF process. Unlike private sector health plans, the DoD uses more disclosure of the evidence presented and allows beneficiaries to provide input before implementation of formulary changes. A major focus of the BAP is the process of formulary decision implementation, especially the process of communication with the 9.7 million TRICARE beneficiaries. For example, the BAP can recommend a longer implementation period for medications moved to Non-Formulary (Tier 3) to balance between allowing necessary time for beneficiary notification versus cost considerations. Moreover, feedback from the BAP was instrumental in the DoD's decision to start sending targeted letters to affected beneficiaries during the up to 180-day implementation period. Implementation periods have been lengthened on several occasions supporting communication with beneficiaries.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

Mandated by law to review and comment on recommendations by the DoD Pharmacy and Therapeutics Committee regarding DoD's Uniform Formulary.

20e. Why is it necessary to close and/or partially closed committee meetings?

Meetings are not closed to the public unless the Department of Defense determines that items on the planned agenda meet the closed meeting provisions of 5 U.S.C. § 552b(c). Pursuant to DoD policy closed meetings can only be authorized by the DoD Sponsor (i.e., the Under Secretary of Defense for Personnel and Readiness), and only after consultation with the Office of the Department of Defense General Counsel.

21. Remarks

Regarding federal staff travel cost, the Defense Health Agency, J3 Pharmacy Operations Division has staff members assigned in San Antonio, Texas. Those staff members travel to and from the Panel's quarterly meeting to participate and present materials. The federal staff travel costs also include local travel for staff members. Title 10, U.S. Code, section 1074g(b), requires the Secretary of Defense to establish a Uniform Formulary Beneficiary Advisory Panel (BAP) under the Federal Advisory Committee Act. The estimated number of Panel meetings is four per year. The relationship between the committee and the decision maker is that no specific reports are submitted to the decision maker. Instead, the committee's advice and recommendations are communicated to the committee's decision maker through its meeting minutes. The committee's decision maker reviews these minutes and makes appropriate decisions for the Department of Defense. Department of Defense (DoD) policy between fiscal year 2007 and 2011 required that subcommittee members be listed separately in the subcommittee section of GSA's Database, even if they were duly appointed members of the parent committee. This policy, in some instances, caused a duplication of entries. Beginning in fiscal year 2012, DoD will only list in the subcommittee section of GSA's Database those who are appointed to just a subcommittee. If an individual is appointed to the parent committee and to one of the committee's authorized subcommittees then his or her subcommittee affiliation will be reflected in the parent committee membership section of GSA's Database.

Designated Federal Officer

Paul J. Hoerner DFO

Committee Members	Start	End	Occupation	Member Designation
Bertin, Richard	01/05/2017	01/05/2021	Commissioned Officer Association (CoA) of the United States Publish Health Service, Inc.	Special Government Employee (SGE) Member

Buchanan, Theresa	07/31/2014	07/31/2019	National Military Family Association	Special Government Employee (SGE) Member
DuTeil, John	01/05/2017	01/05/2021	United States Army Warrant Officer's Association	Special Government Employee (SGE) Member
Hostettler, Charles	03/22/2017	03/22/2021	Association of Military Surgeons of the United States	Special Government Employee (SGE) Member
Joshi, Sarika	01/05/2017	01/05/2021	Health Net Federal Services	Special Government Employee (SGE) Member
Ostrowski, Jon	01/05/2017	01/05/2021	Non Commissioned Officer's Association	Special Government Employee (SGE) Member
Walker, Suzanne	01/05/2017	01/05/2021	Military Officers Association of America	Special Government Employee (SGE) Member

Number of Committee Members Listed: 7

Narrative Description

The Uniform Formulary Beneficiary Advisory Panel provides a forum for input into the development and sustainment of the pharmacy benefit for all Department of Defense (DoD) beneficiaries.

What are the most significant program outcomes associated with this committee?

Checked if Applies

- Improvements to health or safety
- Trust in government
- Major policy changes
- Advance in scientific research
- Effective grant making
- Improved service delivery
- Increased customer satisfaction
- Implementation of laws or regulatory requirements
- Other

Outcome Comments

NA

What are the cost savings associated with this committee?

Checked if Applies

- None
- Unable to Determine
- Under \$100,000
- \$100,000 - \$500,000
- \$500,001 - \$1,000,000
- \$1,000,001 - \$5,000,000

\$5,000,001 - \$10,000,000

Over \$10,000,000

Cost Savings Other

Cost Savings Comments

The recommendations made by the Panel do not attribute to a cost savings to the Department of Defense.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

811

Number of Recommendations Comments

The Panel made 60 recommendations during FY 2018. The Panel makes comments to the P&T Committee recommendations for changes to the Uniform Formulary, implementation timelines, and prior authorization criteria. To date the Panel has made 811 recommendations. The recommendations for the September 2018 meeting are not included in this total

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

98%

% of Recommendations Fully Implemented Comments

The Director, Defense Health Agency, is required to consider the Panel's comments prior to his final decisions.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

2%

% of Recommendations Partially Implemented Comments

The committee may recommend a shorter or longer implementation period. They may also reject a recommendation. The Director, Defense Health Agency makes the final decision.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes No Not Applicable

Agency Feedback Comments

Minutes from the DoD Pharmacy & Therapeutics Committee and Uniform Formulary Beneficiary Advisory Panel are posted and available to Panel members.

What other actions has the agency taken as a result of the committee's advice or recommendation?

	Checked if Applies
Reorganized Priorities	<input type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

Action Comments

NA

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

	Checked if Applies
Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input type="checkbox"/>
Other	<input type="checkbox"/>

Access Comments

N/A